Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponesimod versus teriflunomide in relapsing multiple sclerosis
2012-000540-10Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2015
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Ponesimod arm with Teriflunomide arm (2 arms). Primary endpoint: Annualized relapse rate. Started Aug 2015; status: completed.
02
Drugs
ponesimodteriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2012-000540-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000540-10.